All In Biotech

Drug Trial Radar · NCT06460506

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 12 Months of Age and Older

Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

50

Actual

Start

Nov 21, 2024

Primary completion

Sep 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Jun 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics (PD) of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA).

Conditions

  • Cystic Fibrosis

Interventions

  • ELX/TEZ/IVADrug

    Fixed-dose combination granules for oral administration.

  • IVADrug

    Granules for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 100

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • The Kids Research Institute Australia

    Nedlands, Australia

  • The Royal Children's Hospital

    Parkville, Australia

  • Queensland Children's Hospital

    South Brisbane, Australia

  • The Hospital for Sick Children

    Toronto, Canada

  • British Columbia Children's Hospital

    Vancouver, Canada

  • Juliane Marie Center, Rigshospitalet

    Copenhagen, Denmark

  • Charité Universitätsmedizin BerlinX

    Berlin, Germany

  • Kinderklinik III, Abt. fur Pneumologie

    Essen, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Erasmus Medical Center

    Rotterdam, Netherlands

  • Inselspital - Universitaetsspital Bern

    Bern, Switzerland

  • Kinderspital Zurich

    Zurich, Switzerland

  • Children and Young Adults Research Unit

    Cardiff, United Kingdom

  • Leeds General Infirmary

    Leeds, United Kingdom

  • Alder Hey Children's NHS Foundation Trust

    Liverpool, United Kingdom

  • Great Ormond Street Hospital for Children

    London, United Kingdom

  • Royal Brompton Hospital

    London, United Kingdom

  • Southampton General Hospital

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.